Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
about
Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitorsThe clinical application of linagliptin in AsiansDipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trialsComparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysisDipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis.Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes.Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agentsComparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparisonDifferential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis.Predictive clinical parameters and glycemic efficacy of vildagliptin treatment in korean subjects with type 2 diabetes.Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India.The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysisDipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials.Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes.Vildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin.The long-term efficacy and safety of DPP-IV inhibitors monotherapy and in combination with metformin in 18,980 patients with type-2 diabetes mellitus--a meta-analysis.Meta-analysis of the cardiovascular outcomes with dipeptidyl peptidase 4 inhibitors: validation of the current FDA mandate.The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes.Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions.Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis.Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies.Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients.Efficacy, safety and impact on β-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and the difference between Asians and Caucasians: a meta-analysis.Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: an observational study.Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION)Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus.Racial and Ethnic Disparities in Prevalence and Care of Patients With Type 2 Diabetes.
P2860
Q26772081-F0613A5D-7F78-4628-B419-3DB69BBD8360Q26781942-05F877C0-7842-4B32-AAC1-2D8B2D821C9CQ28294225-6681383A-83A2-447C-9D12-6195434CA254Q28546797-19C86E38-E1FC-48D5-AC56-6B8B34549A18Q30846870-253CDC53-F1E4-4934-830B-49AE2CAB4B43Q33633710-EF351685-3534-4F55-9E6C-865A0C2AF090Q33731748-BE56DE2A-4891-43A4-BA93-AEE1A272261BQ33785197-5DAABA36-71A3-4B0F-9AD3-966E2010C427Q36124544-D78038A2-B860-4DAE-8685-86EE15259A21Q36628919-14436C9F-615B-4721-BFDA-75EC0CB6B224Q36867463-F782CC31-2495-47AD-A70A-2DC78EC36D10Q37030680-3CF10805-10E1-4D4B-A43A-BAA5B32BB80AQ37072773-21B186F3-295E-4FD7-89E7-08EEA46B9F23Q37101632-964DF35A-0649-42D6-94A8-E9C98F1BA950Q37471910-D3AB0811-E4BC-42D7-942B-F7DC4452F7D2Q38196747-47EEE0A7-24B1-4790-AF9E-48794667C820Q38200923-DE26EDA4-62BE-4F1C-9928-AC870C1BD55EQ38211881-40199709-19F0-4147-8A17-AE1548071B24Q38212472-F680DCDF-BD79-4B32-AE4E-2AA597BD9C9AQ38682317-0F9C718C-72A1-4EA1-87FF-E29BAE0C2106Q38795046-F61E01EC-A364-45D5-9FE2-FB66FA891253Q38899869-0103201A-C270-4EA1-A32B-227311698D32Q39108666-8D924556-C548-49F8-B2BA-80E30946DBEEQ39190208-728FC68A-B25D-4992-A43A-FE38B6CD80D7Q40651201-EAE5F6A0-D470-4920-B797-318A85C7128DQ40803621-F72B2FFF-51B7-4EC0-BF74-6352F056D894Q41759692-2AF644C8-F020-4462-8FE3-740D9CDEAB39Q44616554-FDF93DC2-0930-4C76-9627-516334D65A20Q47173429-3AEAE8DF-5DC8-4BBD-BB05-A9EFF3471F7AQ51281907-9C03CE9B-D2B9-43C0-8436-489AE629F863Q51303693-209D2349-3E6C-4F21-B784-28AAFB3C0072Q53988383-0A43E7FC-948A-4D62-B484-E4DE2370F03E
P2860
Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Efficacy and tolerability of v ...... with type 2 diabetes mellitus.
@en
Efficacy and tolerability of v ...... with type 2 diabetes mellitus.
@nl
type
label
Efficacy and tolerability of v ...... with type 2 diabetes mellitus.
@en
Efficacy and tolerability of v ...... with type 2 diabetes mellitus.
@nl
prefLabel
Efficacy and tolerability of v ...... with type 2 diabetes mellitus.
@en
Efficacy and tolerability of v ...... with type 2 diabetes mellitus.
@nl
P2093
P2860
P1476
Efficacy and tolerability of v ...... with type 2 diabetes mellitus.
@en
P2093
Institution Investigators
P2860
P304
P356
10.1111/J.1463-1326.2012.01593.X
P577
2012-04-01T00:00:00Z